Healthcare provider profile · identity verified

John D. Waldron, MD

Family Practice · LOS ANGELES, CA · NPI 1649347642

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	651	224
Amlodipine Besylate	Amlodipine Besylate	273	103
Lisinopril	Lisinopril	264	91
Losartan Potassium	Losartan Potassium	258	95
Rosuvastatin Calcium	Rosuvastatin Calcium	208	75
Levothyroxine Sodium	Levothyroxine Sodium	192	54
Simvastatin	Simvastatin	187	58
Omeprazole	Omeprazole	173	68
Tamsulosin Hcl	Tamsulosin Hcl	151	52
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	143	52
Atenolol	Atenolol	138	44
Hydrochlorothiazide	Hydrochlorothiazide	135	47
Metformin Hcl	Metformin Hcl	131	46
Potassium Chloride	Potassium Chloride	122	50
Trazodone Hcl	Trazodone Hcl	122	33
Metformin Hcl Er	Metformin Hcl	120	47
Pradaxa	Dabigatran Etexilate Mesylate	117	33
Pantoprazole Sodium	Pantoprazole Sodium	116	33
Bisoprolol Fumarate	Bisoprolol Fumarate	114	39
Albuterol Sulfate Hfa	Albuterol Sulfate	108	47
Furosemide	Furosemide	98	39
Finasteride	Finasteride	96	30
Metoprolol Tartrate	Metoprolol Tartrate	89	30
Meloxicam	Meloxicam	84	39
Glipizide	Glipizide	82	28
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	82	17
Lorazepam	Lorazepam	77	21
Terazosin Hcl	Terazosin Hcl	75	27
Alendronate Sodium	Alendronate Sodium	74	27
Ozempic	Semaglutide	73	suppressed
Alprazolam	Alprazolam	68	13
Zolpidem Tartrate	Zolpidem Tartrate	62	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	60	17
Glipizide-Metformin	Glipizide/Metformin Hcl	59	24
Alvesco	Ciclesonide	58	18
Gabapentin	Gabapentin	58	28
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	58	21
Ibuprofen	Ibuprofen	50	14
Carvedilol	Carvedilol	49	16
Clopidogrel	Clopidogrel Bisulfate	47	15
Tramadol Hcl	Tramadol Hcl	44	16
Prednisone	Prednisone	40	28
Allopurinol	Allopurinol	38	15
Hydralazine Hcl	Hydralazine Hcl	38	suppressed
Jardiance	Empagliflozin	37	12
Sertraline Hcl	Sertraline Hcl	37	14
Spironolactone	Spironolactone	34	12
Humulin N Kwikpen	Insulin Nph Human Isophane	32	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	32	suppressed
Donepezil Hcl	Donepezil Hcl	31	suppressed
Metoprolol Succinate	Metoprolol Succinate	31	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	31	18
Acetaminophen-Codeine	Acetaminophen With Codeine	30	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	30	suppressed
Xarelto	Rivaroxaban	30	suppressed
Humulin N	Insulin Nph Human Isophane	28	suppressed
Lovastatin	Lovastatin	28	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	28	suppressed
Fenofibrate	Fenofibrate	27	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	27	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	27	suppressed
Chlorthalidone	Chlorthalidone	26	suppressed
Eliquis	Apixaban	26	suppressed
Victoza 2-Pak	Liraglutide	26	suppressed
Warfarin Sodium	Warfarin Sodium	24	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	23	11
Fluocinonide	Fluocinonide	23	suppressed
Fluticasone Propionate	Fluticasone Propionate	23	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	23	suppressed
Mirtazapine	Mirtazapine	23	12
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	22	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	22	suppressed
Estradiol	Estradiol	21	suppressed
Ondansetron Odt	Ondansetron	21	suppressed
Acyclovir	Acyclovir	20	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	20	suppressed
Hydrocortisone	Hydrocortisone	18	11
Methocarbamol	Methocarbamol	18	suppressed
Nystatin	Nystatin	18	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	18	17
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	17	17
Dicyclomine Hcl	Dicyclomine Hcl	17	suppressed
Montelukast Sodium	Montelukast Sodium	17	suppressed
Temazepam	Temazepam	17	suppressed
Colchicine	Colchicine	16	suppressed
Famotidine	Famotidine	16	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	16	suppressed
Humulin R	Insulin Regular, Human	15	suppressed
Methimazole	Methimazole	15	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	15	suppressed
Clobetasol Propionate	Clobetasol Propionate	14	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	14	suppressed
Clonazepam	Clonazepam	13	suppressed
Digoxin	Digoxin	13	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Baclofen	Baclofen	12	suppressed
Duloxetine Hcl	Duloxetine Hcl	12	suppressed
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	12	12
Glipizide Er	Glipizide	12	suppressed
Naproxen	Naproxen	12	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	12	suppressed
Citalopram Hbr	Citalopram Hydrobromide	11	suppressed
Lactulose	Lactulose	11	suppressed
Sure Comfort Pen Needle	Pen Needle, Diabetic	11	suppressed
Tradjenta	Linagliptin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error